Find out more ways to treat psoriasis in the future

Published Date: 02 Mar 2023

According to MBA MD Andrew Blauvelt, the development of oral biologics and early treatment to replace the disease is a possibility.

Read Full News

Latest News

Dermocosmetics: Are Therapeutic Cosmetics Real?

From acne to rosacea, growing evidence shows targeted dermocosmetics can serve as monotherapy for mild disease or as adjunctive care, improving outcomes and treatment tolerability.

Cutaneous Appendageal Tumors: Worse Outcomes in Black People

Black patients wait weeks longer for therapy than White patients following diagnosis with rare skin cancer, and on average, deaths occur earlier.

Barriers Disrupt Isotretinoin Access in Underserved Teens

Most underserved teens report barriers to isotretinoin access, a survey found.

Adalimumab and Ixekizumab Show Similar Joint Outcomes in PsA

Adalimumab and ixekizumab show comparable effectiveness in improving joint outcomes and achieving remission in patients with psoriatic arthritis over 12 months, according to a real-world study.

Doxycycline for Acne: Impact on STIs

The lower risk for composite bacterial STI in patients taking doxycycline for acne is driven primarily by reduced risk for chlamydia, according to an analysis of TriNetX data.

India's 'Mounjaro Brides': Weight-loss Injections Become Part Of Pre-wedding Preparation

Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India.

Todays Updates

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Todays Updates

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Latest News

From acne to rosacea, growing evidence shows targeted dermocosmetics can serve as monotherapy for mild disease or as adjunctive care, improving outcomes and treatment tolerability.

Black patients wait weeks longer for therapy than White patients following diagnosis with rare skin cancer, and on average, deaths occur earlier.

Most underserved teens report barriers to isotretinoin access, a survey found.

Adalimumab and ixekizumab show comparable effectiveness in improving joint outcomes and achieving remission in patients with psoriatic arthritis over 12 months, according to a real-world study.

The lower risk for composite bacterial STI in patients taking doxycycline for acne is driven primarily by reduced risk for chlamydia, according to an analysis of TriNetX data.

Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India.

News All Time

Dermatomyositis: Targeted Drug Shows Promise vs Placebo

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Melasma: A New Era of Topical Treatment Options Galore

Combination therapies remain key as multiple agents for melasma hit the market.

Research Uncovers Mental Health Toll of Alopecia on Women

Black women are at greater risk for depression and anxiety, and scarring forms are linked to more disorders.

ICI-Related Toxicity Diagnoses Differ for Dark vs Light Skin

A review of published studies suggests that skin toxicities related to checkpoint inhibitors may be managed differently in patients with skin of color vs lighter skin tones.

Consensus Defines Vitiligo Severity, Relapse Beyond BSA

An international consensus study establishes standardized definitions for vitiligo severity and relapse, emphasizing that body surface area alone is insufficient to capture disease burden.

First-Line Biologics May Improve Psoriasis Outcomes

Biologics as a first-line systemic therapy are associated with better clinical outcomes and lower risks for chronic comorbidities in patients with moderate-to-severe psoriasis.

Pfizer-Valneva Lyme Vaccine Shows More Than 70% Efficacy but Misses Key Goal

Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, ⁠even as it missed its main goal.

Can Mpox Vaccine Immunity Last for 5 Years?

The modified vaccinia Ankara-Bavarian Nordic vaccine induces sustained immune memory for up to 5 years, and a single booster dose at 5 years sharply raises antibody levels, a prospective study shows.

FDA Approves Dermal Filler for Temple Hollowing Indication

Loss of temple volume may be accelerated in people rapidly losing weight with medication.

Higher Mortality Risk Seen in axSpA, PsA in Real-World Study

Patients with axial spondyloarthritis and psoriatic arthritis face an elevated risk for all-cause mortality compared with the general population, and the risk is reduced with b/tsDMARD treatment.

Do Diet Trends Improve Health? A Clinical Take

Learn which diet trends have scientific support — clean eating, detox, glow food and plant-based diets influence health differently and require individualized clinical counseling.

Exclusive-Child Vaccination Rate Drops Sharply in Michigan as RFK Jr Influences Policy

Vaccination rates among young children in Michigan dropped sharply during the first year of the Trump administration, a Reuters analysis of state data shows, providing an...

FDA Approves Icotrokinra for Moderate-to-Severe Psoriasis

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

Lutikizumab Offers Relief for Refractory HS

Lutikizumab improves clinical responses and pain outcomes in patients with hidradenitis suppurativa after anti-TNF failure in a phase 2 study.

Novo Nordisk Patent Expiry Opens Door to Cheaper Weight-Loss Drugs in India

India’s diabetes and weight-loss drug market faces a shake-up as Novo Nordisk’s semaglutide patent expires, opening the door to cheaper generics.

FDA OKs Linerixibat for Cholestatic Pruritus

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.

Recommended News For You

Researchers have determined that malignancy hibernation will be the next front in the fight against breast cancer.

Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.

Additional imaging techniques can detect early stage cancers missed by mammograms in women with dense breasts

We Don't Always Know What's 'Best' for Our Patients

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

Early palliative care billing up from 2010 to 2019 for advanced cancer

Recommended Articles For You

Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options  

Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment 

Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy 

Unlocking the Secrets of Follicular Cells: Exploring the Potential of Stem Cell Research 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Alkem introduces cetuximab under the trade name Cetuxa in India.

2.

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

3.

Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening

4.

Hybrid imaging test combines antibody and radioisotope for early lung cancer detection

5.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

1.

Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy

2.

Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment

3.

A Visual Guide to Understanding Breast Cancer Staging

4.

CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma: A Comprehensive Review

5.

Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

2.

Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

3.

Exploring the Hospitalization Burden in Refractory and Relapsed ALL

4.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

5.

Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot